New this year, the Next-Generation Immunotherapies conference examines the novel modalities and engineering strategies that are driving the future of immuno-oncology, immune disorders, and rare diseases. Topics include new constructs, designs and MOAs of cell-based immunotherapies, vaccines, checkpoints and agonists, that strive to overcome the challenges of prior-generations, and improve safety and efficacy profiles.